Issues with reporting and interpretation of Khan et al. 2021

Abstract

Abstract A recent publication in BMC Infectious Diseases concerning the use of convalescent plasma for the treatment of COVID-19 had a number of major issues. This correspondence details specific instances of unclear reporting as well as major omissions when discussing the context of the trial. These render the study's findings and conclusions misleading.

Keywords

• Trials Transparency
• Trial Reporting
• Trial Registration
• Convalescent Plasma
• Covid-19